NCCN now recognizes personalized, tumor-informed ctDNA-MRD as a prognostic and predictive biomarker in MIBC, extending ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the activation of the NRG Oncology trial, ARCHER (NRG-GU015), a ...

Real-world findings from >550 plasma samples highlight prognostic and predictive value of Signatera for adjuvant decision-making and immunotherapy monitoring This study analyzed 555 prospectively ...

A total of 156 patients with primary breast cancer were monitored clinically for up to 12 years after surgery and adjuvant chemotherapy. Semiannual blood samples were prospectively collected, and ...

US-based clinical genetic testing company Natera said that its Signatera test will be utilised in the newly activated ARCHER trial, a Phase III study sponsored by NRG Oncology. The trial focuses on ...

Natera NTRA recently announced that Signatera has received PMDA approval in Japan for use in colorectal cancer (CRC) patients ...

Stage 3 colorectal cancer patients with MRD benefit from Celebrex addition to chemotherapy, showing a 40% risk reduction in death for Signatera-positive patients. Celebrex improved disease-free and ...

My husband’s cancer came back this summer after not being evident for almost two years. With advances in cancer surveillance, we now speak of cancer survivors being cancer-free far less frequently. If ...

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that its personalized and tumor-informed molecular residual disease (MRD) test, ...

Randomized study aims to reduce treatment burden for patients and utilizes Signatera to monitor for disease recurrence AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA) (NASDAQ: NTRA), a global ...